{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:45:09Z","timestamp":1787010309057,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      DOTA-ibandronic acid (DOTA-IBA) is a recently developed prodrug targeting bone metastases. Labeling with\n                      <jats:sup>68<\/jats:sup>\n                      Ga\/\n                      <jats:sup>177<\/jats:sup>\n                      Lu (\n                      <jats:sup>68<\/jats:sup>\n                      Ga\/\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-IBA) induces good curative effects and safety in these patients. However, there has been no evaluation of the safety and effectiveness of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-IBA in cases of multiple bone metastases. Here, the hematological toxicity and efficacy of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-IBA in cases of multiple bone metastases were investigated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants and Methods:<\/jats:title>\n                    <jats:p>\n                      Twenty-eight cases of multiple bone metastases were enrolled in the analysis. Following\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-IBA treatment, blood biomarkers were monitored to evaluate the safety of treatment. Karnofsky Performance Status assessments (KPS), Visual Analogue Scale (VAS) pain scores, and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTA-IBA PET\/CT follow-up were utilized for evaluation of the curative effect.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The 28 enrolled patients with multiple bone metastases had a median treatment cycle of 3. The baseline hematological parameters of 25 patients (89%) were abnormal. Post-treatment follow-up showed that blood counts remained essentially unchanged from baseline, with only one patient (4%) developed new grade 3 anemia. A 79% (22\/28) rate of bone pain remission was observed and follow-up\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTA-IBA PET\/CT images showed that 15 cases (54%, 15\/28) had partial remission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      No serious adverse events were observed in patients with multiple bone metastases who received\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-IBA. The therapeutic agent demonstrated promising efficacy, particularly for pain control and improved quality of life, suggesting that\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-IBA is a safe, effective therapeutic option for this population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006475","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:00:31Z","timestamp":1776276031000},"page":"565-569","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Excellent Response to 177Lu-DOTA-IBA Therapy of Patients With Multiple Skeletal Metastases"],"prefix":"10.1097","volume":"51","author":[{"given":"Qingchu","family":"Hua","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, PR China"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation, Luzhou, Sichuan, PR China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, PR China"},{"name":"The People\u2019s Hospital of Aba Tibetan and Qiang Autonomous Prefecture, Aba, Sichuan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, PR China"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation, Luzhou, Sichuan, PR China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, PR China"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation, Luzhou, Sichuan, PR China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, PR China"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation, Luzhou, Sichuan, PR China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, PR China"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation, Luzhou, Sichuan, PR China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, PR China"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation, Luzhou, Sichuan, PR China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"e2419966","DOI":"10.1001\/jamanetworkopen.2024.19966","article-title":"Bone pain and survival among patients with metastatic, hormone-sensitive prostate cancer: a secondary analysis of the SWOG-1216 trial","volume":"7","author":"Gebrael","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF02625949","article-title":"Surgical treatment of bone metastases","volume":"28","author":"Mutschler","year":"1996","journal-title":"Acta Chir Austriaca"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2020.38.15_suppl.3638","article-title":"Safety, tolerability, and preliminary pharmacokinetic\/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: a multicenter, open-label, dose-escalation, phase I clinical study","volume":"38","author":"Li","year":"2020","journal-title":"J Clin Oncol"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"e183242","DOI":"10.1001\/jamanetworkopen.2018.3242","article-title":"Development and validation of a nomogram for assessing survival in patients with metastatic lung cancer referred for radiotherapy for bone metastases","volume":"1","author":"Yap","year":"2018","journal-title":"JAMA Netw Open"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2967\/jnumed.112.112482","article-title":"Bone-seeking radiopharmaceuticals for treatment of osseous metastases, part 1: \u03b1 therapy with 223Ra-dichloride","volume":"55","author":"Pandit-Taskar","year":"2014","journal-title":"J Nucl Med"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","article-title":"EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer","volume":"45","author":"Poeppel","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00259-018-3947-x","article-title":"EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides","volume":"45","author":"Handkiewicz-Junak","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/RLU.0000000000003667","article-title":"Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI04","volume":"46","author":"Kuyumcu","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.semnuclmed.2024.05.006","article-title":"Targeted radiopharmaceutical therapy for bone metastases","volume":"54","author":"Mahajan","year":"2024","journal-title":"Semin Nucl Med"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2967\/jnmt.113.132266","article-title":"\u00b9\u2077\u2077Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases","volume":"42","author":"Shinto","year":"2014","journal-title":"J Nucl Med Technol"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13550-020-00709-y","article-title":"[177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results","volume":"10","author":"Yadav","year":"2020","journal-title":"EJNMMI Res"},{"key":"R14-20260605","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/pros.23974","article-title":"Influence of short-term dexamethasone on the efficacy of 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"80","author":"Derlin","year":"2020","journal-title":"Prostate"},{"key":"R16-20260605","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1148\/radiographics.9.2.2467331","article-title":"Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone","volume":"9","author":"Robinson","year":"1989","journal-title":"Radiographics"},{"issue":"suppl 1","key":"R17-20260605","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1007\/s00259-004-1540-y","article-title":"153Sm-EDTMP for bone pain palliation in skeletal metastases","volume":"31","author":"Maini","year":"2004","journal-title":"Eur j nucl med mol i"},{"key":"R18-20260605","first-page":"953","article-title":"Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases","volume":"44","author":"Liepe","year":"2003","journal-title":"J Nucl Med"},{"key":"R19-20260605","first-page":"1839","article-title":"Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I\/II trial","volume":"34","author":"Collins","year":"1993","journal-title":"J Nucl Med"},{"key":"R20-20260605","doi-asserted-by":"crossref","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R21-20260605","doi-asserted-by":"crossref","first-page":"1027792","DOI":"10.3389\/fonc.2022.1027792","article-title":"Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"R22-20260605","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1021\/acs.molpharmaceut.2c00978","article-title":"Lutetium177-labeled DOTA-Ibandronate: a novel radiopharmaceutical for targeted treatment of bone metastases","volume":"20","author":"Wang","year":"2023","journal-title":"Mol pharmaceut"},{"key":"R23-20260605","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/RLU.0000000000004634","article-title":"Safety and efficacy of 68 Ga- or 177 Lu-labeled DOTA-IBA as a novel theranostic radiopharmaceutical for bone metastases: a Phase 0\/I study","volume":"48","author":"Qiu","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R24-20260605","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13550-024-01094-6","article-title":"Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases","volume":"14","author":"Li","year":"2024","journal-title":"EJNMMI Res"},{"key":"R25-20260605","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/1450-1147.157124","article-title":"Metastatic bone pain palliation using (177)Lu-ethylenediaminetetramethylene phosphonic acid","volume":"14","author":"Alavi","year":"2015","journal-title":"World J Nucl Med"},{"key":"R26-20260605","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00259-014-2862-z","article-title":"(177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study","volume":"42","author":"Agarwal","year":"2015","journal-title":"Eur j nucl med mol i"},{"key":"R27-20260605","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/RLU.0b013e318279bf4d","article-title":"Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study","volume":"38","author":"Yuan","year":"2013","journal-title":"Clin Nucl Med"},{"key":"R28-20260605","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2385-1-2","article-title":"Re-HEDP: pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose","volume":"1","author":"Savio","year":"2001","journal-title":"BMC Nucl Med"},{"key":"R29-20260605","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s002590050017","article-title":"Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases","volume":"27","author":"Palmedo","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"R30-20260605","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1874471015666220806141755","article-title":"Dosimetric comparison of different radionuclides used in metastatic bone disease treatment","volume":"16","author":"K\u00f6kk\u00fcl\u00fcnk","year":"2023","journal-title":"Curr Radiopharm"},{"key":"R31-20260605","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.1989.7.12.1926","article-title":"A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases","volume":"7","author":"Turner","year":"1989","journal-title":"J Clin Oncol"},{"key":"R32-20260605","first-page":"202","article-title":"177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis","volume":"23","author":"Chakraborty","year":"2008","journal-title":"Cancer biother radio"},{"key":"R33-20260605","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2020.05.004","article-title":"Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study","volume":"78","author":"Gafita","year":"2020","journal-title":"Eur Urol"},{"key":"R34-20260605","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.3390\/cancers13164017","article-title":"Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement","volume":"13","author":"Groener","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R35-20260605","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","article-title":"Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer","volume":"49","author":"Lawal","year":"2022","journal-title":"Eur j nucl med mol i"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:00:11Z","timestamp":1780689611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006475","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"2025-10-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}